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Frederic S. Resnic, MD, MSc, FACC, and Akshay Desai, MD, MPH, FACCThe 58thAnnual Scientific Sessions of theAmericanCollege
of Cardiology (ACC), held March 28 through 31, 2009, in
Orlando, Florida, provided a forum for the initial release of
clinical trial data as well as comprehensive review of many
topics of significant interest to cardiothoracic surgeons.
CORONARYARTERY DISEASE AND CORONARY
STENTS
Quality of Life With Stents Versus Surgery in
Treatment of Multivessel and Left Main Coronary
Artery Disease
The SYNTAX investigators explored the quality of life
and cost-effectiveness of the strategy of percutaneous coro-
nary intervention (PCI) versus coronary artery bypass graft-
ing (CABG) for left main or multivessel coronary artery
disease in this international randomized study of over 1600
patients. The group had previously published the 1-year out-
comes from the study, which demonstrated similar rates of
death andmyocardial infarction at 12months, with increased
rates of repeat revascularization for the patients treated with
PCI.1 Dr David Cohen reported that although angina relief
was slightly better with CABG than drug-eluting stents
(DES) at 6 and 12 months, the differences were very small,
and the overall costs (including hospitalization and rehabili-
tation) were significantly higher at 1 year for the patients
treated with CABG. The 1-year cost-effectiveness (based
onUShealth care costs) significantly favoredPCI for patients
with low and moderate levels of angiographic complexity;
CABG was economically attractive for patients with the
most severe angiographic complexity (SYNTAX score>
32). Another cost-effectiveness analysis of the SYNTAX pa-
tients is planned when the 5-year follow-up data become
available, which should allow some insight into the long-
term cost-effectiveness of CABG versus PCI for patients
with both multivessel coronary artery disease as well as left
main coronary artery disease.2
IMPROVING SAFETYAND OUTCOMES OF
CORONARY STENTS
Several studies presented during ACC 2009 confirmed the
safety of DES as compared with traditional bare metal stents
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National Cardiovascular Data Registry (NCDR) dataset
through linkage of case records to the Medicare claims data-
base to analyze clinical outcomes up to 30 months after stent
implantation. This study compared the clinical outcomes of
over 260,000 patients treated at more than 650 centers
throughout the United States between January 2004 and De-
cember 2006 and demonstrated a 25% reduction in adjusted
rates of death or myocardial infarction in the patients treated
with DES as compared with those treated with BMS. The
benefit of DES was sustained to 30 months following stent
implantation, reinforcing the relative safety of DES as com-
pared with BMS.3
Two trials were reported that evaluated the impact of
acute (as a loading dose) statin therapy, administered imme-
diately prior to PCI, on the rates of periprocedural myocar-
dial infarction. The NAPLES II investigators randomized
668 patients who were scheduled to have elective PCI and
who were not on statin therapy already to receive an 80-
mg atorvastatin loading dose 24 hours prior to the procedure
versus placebo. The study found that patients receiving the
atorvastatin loading dose had a 44% reduction in the rates
of postprocedural myocardial infarction (defined as creati-
nine kinase MB> 33 upper limit of normal).4 The AR-
MYDA-RECAPTURE investigators explored the benefits
of reloading high-dose statins immediately prior to PCI in
patients on chronic statin therapy. The study found a 63%
reduction in the combined major cardiovascular events and
a 44% reduction in the risk of periprocedural myocardial in-
farction in the 352 patients randomized to receive a reloading
dose of a statin therapy in the trial.5
HEART FAILURE AND SURGICALVENTRICULAR
REMODELING
The Hypothesis 2 Substudy of the Surgical Treatment for
Ischemic Heart Failure (STICH) trial was designed to test the
proposition that surgical venticular remodeling (SVR) added
to CABG is superior to CABG alone for the management of
patients with coronary artery disease (left ventricular ejection
fraction  35%) and a dominant region of anterior akinesis
or dyskinesis suitable for treatment with SVR. The primary
outcome of the trial was a composite of death from any cause
or hospitalization for cardiac causes. One thousand patients
were recruited from 96 medical centers in 23 countries. De-
spite a statistically greater reduction in left ventricular size
with SVR relative to CABG alone, over a median 48 months
of follow up, no difference was observed in the occurrence of
the primary outcome between the CABG group and theardiovascular Surgery c Volume 138, Number 3 795
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death for CABG alone (5%) and for the combined procedure
(6%) were similar and low overall. Although key patient
subgroupswere examined for a treatment interaction, no sub-
set experiencing benefit from SVR þ CABG over CABG
alone was identifiable. Overall, these results emphasize
that the routine addition of SVR to CABG in patients with re-
duced ejection fraction and coronary artery disease is not
beneficial. Though the specific reasons for discrepancy be-
tween the results of this randomized trial experience and
the prior observational data are unclear, the data do highlight
that the remodeling benefits of neurohormonal antagonism
cannot be replicated or augmented through direct reduction
of left ventricular volumes in the operating room. The value
of CABG (with or without SVR) relative to medical therapy
alone in patients with coronary artery disease and reduced
ejection fraction is the focus of the ongoing Hypothesis 1
Subgroup of the STICH trial.6
CATHETER-BASED TREATMENT FORVALVULAR
HEART DISEASE
The treatment of calcific aortic stenosis using catheter-
based aortic valve prostheses remains an area of intense in-
terest within the cardiovascular community, with several
live cases broadcast demonstrating the evolving technolo-
gies throughout the ACC 2009 meeting and multiple plenary
sessions dedicated to the exploration of these devices and
techniques. Two technologies were the focus of demonstra-
tions: the Edwards Sapien balloon-expandable transcatheter
valve and the CoreValve self-expanding stented valve sys-
tem. The international experience and outcomes in several
thousand patients implanted with each device were reviewed
and discussed at ACC-2009. In the United States, the pivotal
randomized trial of the Edwards valve, the PARTNER
study, is approaching completion of enrollment, and initial
results are anticipated in 2010. The US pivotal trial for the
Medtronic CoreValve system is anticipated to begin within
the next 12 months in the United States, pending approval
of final trial design by Food and Drug Administration
(FDA).
STRATEGIES TO REDUCE STROKE RISK IN
ATRIAL FIBRILLATION
Alternative Medication Strategies to Prevent Stroke
in Atrial Fibrillation
Although vitamin K antagonists (such as warfarin) reduce
the risk of stroke in patients with atrial fibrillation, nearly
one-half of such patients are judged by their physicians to
be unsuitable for this therapy and are treated with aspirin
alone. The Atrial Fibrillation Clopidogrel Trial with Irbesar-
tan for Prevention of Vascular Events (ACTIVE-A) trial ran-
domized 7554 patients with atrial fibrillation and 1 or more
additional risk factors for stroke and who were deemed un-
suitable for warfarin therapy to treatment with clopidogrel796 The Journal of Thoracic and Cardiovascular Su(75 mg/d) or placebo in addition to aspirin (recommended
dose, 75–100 mg) over a median follow-up of 3.6 years.
The primary outcome, a composite of major vascular events
including stroke, myocardial infarction, systemic embolism,
or death from vascular causes, was reduced by 11%with the
combination of clopidogrel and aspirin relative to aspirin
alone, a reduction powered in large part by a highly signifi-
cant 28% reduction in stroke. This benefit accrued at the
expense of a substantial increase in major bleeding with clo-
pidogrel and aspirin in combination (2.0% per year) relative
to aspirin alone (1.3% per year).7,8
These data highlight that the addition of clopidogrel pro-
vides incremental reduction in vascular events over treat-
ment with aspirin alone at the cost of more bleeding.
Although warfarin remains the treatment of choice for
patients with atrial fibrillation at high risk for stroke (data
from ACTIVE-W arm of the same program highlighted
that therapy with a vitamin K antagonist reduces the rate
of stroke by 42% relative to therapy with clopidogrel plus
aspirin9), these data provide support for a potential alterna-
tive to aspirin monotherapy in the large proportion of pa-
tients who are thought to be ineligible for warfarin therapy.
LEFTATRIAL APPENDAGE OCCLUSION DEVICE
TO PREVENT STROKE IN PATIENTS WITH
ATRIAL FIBRILLATION
Among patients with atrial fibrillation who are eligible for
warfarin therapy, PROTECT-AF trial examined the role of
percutaneous device closure of the left atrial appendage
(LAA) as a therapeutic alternative to warfarin therapy. The
study randomized 800 patients with nonvalvular atrial fibril-
lation eligible for warfarin therapy from 59 enrolling centers
in the United States and Europe in a 2:1 fashion to therapy
with the Watchman device (Atritech, Plymouth, Minn), an
LAA occluder placed distal to the ostium of the LAA to
occlude flow and prevent the migration of thrombus, or
long-term warfarin in a noninferiority design. The device
is delivered via a catheter placed in the left atrium via trans-
septal catheterization. Although initially also treated with
warfarin to allow for endothelialization, 87% of patients
in the device arm were able to discontinue warfarin at 45
days. After 900 patient-years of follow-up, the strategy of
LAA occlusion was associated with a statistically significant
reduction in hemorrhagic stroke relative to warfarin and was
noninferior to warfarin with regard to all-cause stroke and
all-cause mortality. However, safety events, particularly
pericardial effusion, were increased by twofold in the device
group.10 (Editor’s note: The Watchman device received rec-
ommendation for approval from the medical review panel of
the FDA on April 23, 2009.)
PREVENTIVE CARDIOLOGY DEVELOPMENTS
The JUPITER trial randomized 17,802 healthy men and
women with both low-density lipoprotein (LDL) cholesterolrgery c September 2009
Resnic and Desai Meeting Proceedingslevels of less than 130 mg per deciliter and high-sensitivity
C-reactive protein (hsCRP) levels of 2.0 mg per liter or
higher to receive rosuvastatin (Crestor) or placebo. The trial
was stopped early at a median follow-up of 1.9 years due to
a 44% reduction in the combined rate of myocardial infarc-
tion, stroke, arterial revascularization, unstable angina, or
death from cardiovascular causes in the rosuvastatin-treated
patients.11 A key new analysis of the JUPITER data pre-
sented at ACC 2009 demonstrated that lowering both LDL
and C-reactive protein results in higher event-free survival
than either intervention alone. Specifically, Ridker and col-
leagues noted that patients in the trial achieving both an LDL
cholesterol<70 mg/dL and hsCRP<2 mg/L experienced
a 65% reduction in vascular events relative to a 33% reduc-
tion among those who achieved only one or neither target.
For patients initiating drug therapy for prophylaxis of car-
diovascular disease, reductions in both LDL cholesterol
and hsCRP appear to be important indicators of the success
of treatment with statin therapy.12
DEVELOPMENTS IN CARDIAC SURGICAL
DEVICE RESEARCH
Dr Davy Cheng presented a meta-regression analysis of
endovascular (TEVAR) versus open repair of thoracic aortic
disease due to trauma, dissection, or degenerative condi-
tions. The analysis of 42 studies, including 5888 patients
treated, demonstrated a significant reduction in overall com-
plications with TEVAR as compared with open surgical re-
pair, with a reduction in death at 30 days of 56%, which was
sustained to 3 years. Other end points including renal dys-
function following intervention and transfusion require-
ments were also reduced in the patients treated with
TEVAR as compared with the patients having open sur-
gery.13 Therefore, these data indicate that, in the absence
of prospective randomized trial data, TEVAR appears to
have clinical advantages over open surgical repair in the
patient groups included in the analyzed studies.
The results of the VentrAssist (VentraCore, New South
Wales, Australia) implantable ventricular assist device
(VAD) bridge to transplant pivotal trial was reported by Dr
Andrew Boyle. Among the first 98 patients treated with this
centrifugal VAD, 85% of patients either were alive with
the pump or had been transplanted successfully, exceedingThe Journal of Thoracic andthe predefined performance goal for this pilot study. In addi-
tion, treated patients experienced significant improvements
in quality of life after implantation of the VentrAssist device.
These results point to the VentrAssist centrifugal VAD
emerging as another mechanical support option as a bridge
to cardiac transplantation.14
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